Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and ...

Learn more Servier has signed an agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in a deal valued at ...

Explore how researchers are using next-generation CRISPR therapies to target the root cause of muscle degeneration.

A new treatment platform developed by researchers at the University of Texas MD Anderson Cancer Center was able to deliver ...

In addition to the upfront fee, Servier has committed up to $1.1 billion in regulatory and commercial milestones to acquire ...

The French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say ...

Atlantic at Acadia University, representatives from Muscular Dystrophy Canada's Nova Scotia branch were on hand fu ...

Health Canada Priority Review targets an expedited 180-day review period for givinostat, reflecting Italfarmaco’s commitment to Canadian DMD ...

Armed with new clinical data, Novartis is planning to talk to global regulators about possible filings for delpacibart braxlosiran (del-brax), which could become the first disease-modifying treatment ...

Your muscles need continuous maintenance to stay strong and healthy. Duchenne muscular dystrophy (DMD) happens when there is a change in a person's genetic instructions that affects the production of ...

Biotech firm Edgewise Therapeutics said on Monday it would sell its experimental muscular dystrophy drug and related business ...

The brothers shared an unbreakable bond while living with Duchenne muscular dystrophy, a rare genetic disorder that causes ...